Integrating buprenorphine prescribing into OTP
Poster of same model.
Integrating buprenorphine prescribing into OTP
Poster of same model.
This is a recording of a training that discusses how to normalize addiction through patient-centered care to improve outcomes and reduce overdose deaths.
These findings suggest that take-home naloxone supplied to patients in opioid treatment programs may be part of a targeted harm-reduction strategy to reduce negative outcomes associated with opioid overdose in the community.
Innovative service modifications to adapt to COVID-19 circumstances primarily involved expanded use of telehealth services (e.g., telemedicine visits for buprenorphine, virtual individual or group therapy sessions, provision of donated or publicly available phones), increased take-home medication allowances for methadone and buprenorphine, expanded uptake of long-acting opioid medications (e.g. extended-release buprenorphine and naltrexone), home delivery of services (e.g. MOUD, naloxone and urine drug screening), outreach and makeshift services for delivering MOUD and naloxone, and provision of a safe supply of opioids.
An opioid treatment program (OTP) and a federally qualified health center (FQHC) partnered to develop and implement an innovative integrated methadone and primary care treatment model. The process for integrating an OTP and FQHC to provide methadone treatment in the primary care setting will be discussed.